New drug tested to shorten ICU stays for rare muscle disease
NCT ID NCT07411963
Summary
This study observes 30 adults in France with a severe, life-threatening flare-up of myasthenia gravis (a rare muscle-weakening disease) who are already in the intensive care unit (ICU). Doctors want to see if giving a newer drug called ravulizumab early, after standard emergency treatments, helps patients get stronger faster and leave the hospital sooner. The study will track patients' recovery over six months but does not test an experimental treatment or change their standard medical care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de NICE
RECRUITINGNice, Alpes-maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.